Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF for drug discovery and mechanism of action (MOA) research

Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bifikafusp alfa is a fusion protein of pro-inflammatory IL-2 and IL19 human mAb fragment (scFv domain) that binds the tumor microenvironment expressed fibronectin extradomain B (EDB). Incorporation of the IL19 binding fragment targets the drug to the tumor, improving selective site accumulation and tumor killing and at the same time reducing the effective dose required to achieve a meaningful response, and reducing the otherwise dose-limiting toxicities associated with high-dose IL-2 administration that would be required to produce the same killing effect.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-761-1mg	1mg	3090
GMP-Bios-INN-761-10mg	10mg	Inquiry
GMP-Bios-INN-761-100mg	100mg	Inquiry
GMP-Bios-INN-761-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF
INN Name	Bifikafusp Alfa
Target	FN/FN1
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	scFv - heavy - kappa
VD LC	scFv - heavy - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Philogen (Sovicille Italy)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0